Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines Part 2.
- Author:
Sollip KIM
1
;
Yeo Min YUN
;
In Suk KIM
;
Sang Hoon SONG
;
Hye In WOO
;
Kyung A LEE
;
Woochang LEE
;
Hyun Jung CHO
;
Misuk JI
;
Hyo Jin CHAE
;
Soo Youn LEE
;
Sail CHUN
Author Information
- Publication Type:Original Article
- Keywords: Pharmacogenetics; Genetic testing; Practice guidelines; Clinical laboratory services
- MeSH: Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Clinical Laboratory Services; Codeine; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Expert Testimony; Genetic Testing; Humans; Insurance; Isoniazid; Korea; Pharmacogenetics; Protein-Tyrosine Kinases; Tamoxifen; Warfarin
- From:Laboratory Medicine Online 2016;6(4):193-213
- CountryRepublic of Korea
- Language:Korean
- Abstract: Pharmacogenetics is a rapidly evolving field and the number of pharmacogenetic tests for clinical use is steadily increasing. However, incorrect or inadequate implementation of pharmacogenetic tests in clinical practice may result in a rise in medical costs and adverse outcomes in patients. This document suggests guidelines for the clinical application, interpretation, and reporting of pharmacogenetic test results based on a literature review and the collection of evidence-based expert opinions. The clinical laboratory practice guidelines encompass the clinical pharmacogenetic tests covered by public medical insurance in Korea. Technical, ethical, and regulatory issues related to clinical pharmacogenetic tests have also been addressed. In particular, this document comprises the following pharmacogenetic tests: CYP2C9 and VKORC1 for warfarin, CYP2C19 for clopidogrel, CYP2D6 for tricyclic antidepressants, codeine, tamoxifen, and atomoxetine, NAT2 for isoniazid, UGT1A1 for irinotecan, TPMT for thiopurines, EGFR for tyrosine kinase inhibitors, ERBB2 (HER2) for erb-b2 receptor tyrosine kinase 2-targeted therapy, and KRAS for anti-epidermal growth factor receptor drugs. These guidelines would help improve the usefulness of pharmacogenetic tests in routine clinical settings.
